AbbVie’s Upadacitinib Benefits Crohn’s Patients in Phase 2 Trial, Supporting Advance to Phase 3

AbbVie’s Upadacitinib Benefits Crohn’s Patients in Phase 2 Trial, Supporting Advance to Phase 3
A Phase 2 trial (NCT02365649) of AbbVie’s investigational compound upadacitinib (ABT-494) showed the treatment had a positive effect in patients with Crohn’s disease, supporting the drug’s advance to Phase 3 trials. Data from the trial, called CELEST, was presented at the Digestive Disease Week 2017 conference May 6-9 in Chicago. The study had particularly focused on

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *